Company News
-
August 31, 2026
Surviving Sepsis: How Diagnostics Can Help Improve Outcomes When Every Hour Matters
For patients at risk of sepsis, time matters. Faster diagnostic information can help healthcare teams identify the cause of infection sooner, supporting earlier better-informed care decisions. -
July 08, 2026
bioMérieux Launches PCR Testing Solution to Verify Probiotic Species in Dietary Supplements Manufacturing
With GENE-UP® PROBIOTIC SPECIES ID, bioMérieux introduces a first-of-its-kind commercialized species-level identification PCR solution for in-house quality control teams and external laboratory partners. -
June 05, 2026
Measuring to reduce environmental impact: how bioMérieux is acting across our diagnostic solutions
Our products’ environmental performance is a core pillar of our commitment to protecting the planet. For several years, bioMérieux has been implementing a continuous improvement approach based on Life Cycle Assessments (LCAs) of our diagnostic solutions. The goal is to measure our products’ impact on the climate and environment across the entire value chain — from manufacturing and customer use to end-of-life management. -
June 03, 2026
Mobilizing diagnostics to support the Ebola response
In line with our public health mission, bioMérieux and BioFire Defense, a bioMérieux company, are mobilizing Ebola diagnostics to support ongoing efforts related to the current Ebola outbreak in Africa. -
April 22, 2026
Preserving the planet to protect health: our commitments and progress
Preserving the planet to protect health: our commitments and progress
Fully aware of today’s climate and environmental challenges, we are taking action to reduce the footprint of our activities, optimize the use of resources, and design increasingly responsible solutions. Since 2019, we have been committed to an ambitious environmental trajectory. Here is an overview of the concrete, measurable, and sustainable actions implemented by our teams around the world.